Point cloud fusion instance effect. حسب Hongliang Zou (20707270)

الموضوعات:

Youthful systemic milieu in young recipients decreased apoptosis and oxidative stress damage in allografts, and promoted proliferation. حسب Chengjun Yu (12136227)

Comparison of detection results between YOLOv5s and P-YOLOv5s-GRNF. حسب Zhongjian Xie (4633099)

الموضوعات:

Force analysis of the system. حسب Jianbo Jia (717814)

الموضوعات:

Structure of YOLOv5s-SBC. حسب Zhongjian Xie (4633099)

الموضوعات:

The working principle of the Welleader system. حسب Jianbo Jia (717814)

الموضوعات:

Structure of P-YOLOv5s-GRNF. حسب Zhongjian Xie (4633099)

الموضوعات:

Graphs showing the mean maximum temperature increase at the position with the highest mean temperature increase (A) and the mean temperature increase across all probes (B) for each... حسب Marsel Ganeyev (21453399)

الموضوعات:

Comparative experiment of different YOLOv5 versions. حسب Zhongjian Xie (4633099)

الموضوعات:

Local mechanism diagram of Welleader system. حسب Jianbo Jia (717814)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات: